News

Date Title View
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Scott Cassady as Regional Sales Director for the Central Region
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 12, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Brad Fuller as Director of National Accounts in its Market Access Department
IRVINE, Calif. --(BUSINESS WIRE)--Feb. 8, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Tad Heitmann as Head of Communications
IRVINE, Calif. --(BUSINESS WIRE)--Feb. 1, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Public Offering of Common Stock
IRVINE, Calif. --(BUSINESS WIRE)--Jan. 23, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma or ocular hypertension and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance and Tim Swan as Director of Sales and Transparency Operations
IRVINE, Calif. --(BUSINESS WIRE)--Jan. 16, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Julia Williams as Director of Medical Affairs
IRVINE, Calif. --(BUSINESS WIRE)--Jan. 2, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Rhopressa® (netarsudil ophthalmic solution) 0.02% Label
Toggle Summary Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa® (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension
Product Approved Ahead of the Scheduled PDUFA Date of February 28, 2018 IRVINE, Calif. --(BUSINESS WIRE)--Dec. 18, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region
IRVINE, Calif. --(BUSINESS WIRE)--Dec. 4, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Paul Bae as Vice President of Human Resources
IRVINE, Calif. --(BUSINESS WIRE)--Dec. 1, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML